


# Kolorektal Kanserde Bağırsak Mikrobiyomunun Rolü

Xiaolun Sun

## 1 Kolorektal kanser (CRC) epidemiyolojisi

Kalın bağırsak, sindirim sistemi uzunluğunun sadece %20'sini ve mukozal yüzey alanının %6'sını oluşturmaya rağmen (Helander ve Fandriks 2014), kolorektal kanser (CRC), gastrointestinal (GI) kanalda teşhis edilen bir numaralı kanserdir ve kolorektal kanser; Amerika Birleşik Devletleri'ndeki (ABD) yeni GI kanserleri vakalarının %44'ünden fazlasını oluşturmaktadır (Siegel ve diğerleri 2019). Neyse ki, yaygın kolonoskopi taraması ve araştırmaların ilerlemesiyle, yaşa göre düzeltilmiş yeni CRC vakalarının oranı 1999'da 100.000 nüfusta 56'dan 2015'te 100.000 nüfusta 38'e (CDC2019) tutarlı bir şekilde düşmüştür, ancak toplam vaka sayıları 1999'da 150.014'ten 2015'te 140.788'e kadar gerilemiştir (Şekil 1a). Tutarlı bir şekilde, yaşa göre ayarlanmış CRC ölüm oranı, 1999'da 100.000 nüfus başına 21'den 2015'te 100.000 nüfus başına 14'e düşmüştür, ancak toplam vaka sayıları 1999'da 57.222'den 2015'te 52.396'ya kadar gerilemiştir (Şekil 1b). Sonuç olarak kolorektal kanser, hem erkek hem de kadınlarda tüm kanserlerin üçüncü en yaygın nedenidir ve ABD'de kansere bağlı ölümlerin ikinci onde gelen nedenidir (Siegel ve ark. 2019). Bu nedenle, CRC'nin yeni vakalarını ve ölüm oranlarını önemli ölçüde azaltmak için gidilecek uzun bir yol olduğu görülmektedir ve CRC'nin altında yatan mekanizmayı araştırmak ve yeni terapötik yaklaşımıları keşfetmek acil bir meseledir.



**Şekil 1.** 1999-2015 yılları arasında yaşa göre belirlenmiş CRC yeni vakaları ve ölümleri. (a) Amerika Birleşik Devletleri'ndeki yeni CRC vakalarının ve ölümlerin oranları. (b) CRC'den kaynaklanan yeni vaka ve ölümlerin toplam sayıları

## Kaynaklar

- Ahn, J., Sinha, R., Pei, Z., Dominianni, C., Wu, J., Shi, J., Goedert, J. J., Hayes, R. B., & Yang, L. (2013). Human gut microbiome and risk for colorectal cancer. *Journal of the National Cancer Institute*, 105, 1907–1911.
- Armelao, F., & de Pretis, G. (2014). Familial colorectal cancer: a review. *World Journal of Gastroenterology*, 20, 9292–9298.
- Arthur, J. C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science*, 338, 120–123.
- Attene-Ramos, M. S., Wagner, E. D., Plewa, M. J., & Gaskins, H. R. (2006). Evidence that hydrogen sulfide is a genotoxic agent. *Molecular Cancer Research*, 4, 9–14.
- Aykan, N. F. (2015). Red Meat and Colorectal Cancer. *Oncology Reviews*, 9, 288.
- Bartosch, S., Woodmansey, E. J., Paterson, J. C., McMurdo, M. E., & Macfarlane, G. T. (2005). Microbiological effects of consuming a symbiotic containing *Bifidobacterium bifidum*, *Bifidobacterium lactis*, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*, 40, 28–37.
- Bellam, N., & Pasche, B. (2010). Tgf-beta signaling alterations and colon cancer. *Cancer Treatment and Research*, 155, 85–103.
- Bonnet, M., Buc, E., Sauvanet, P., Darcha, C., Dubois, D., Pereira, B., Dechelotte, P., Bonnet, R., Pezet, D., & Darfeuille-Michaud, A. (2014). Colonization of the human gut by *E. coli* and colorectal cancer risk. *Clinical Cancer Research*, 20, 859–867.
- Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A. B., & Maisonneuve, P. (2008). Smoking and colorectal cancer: a meta-analysis. *JAMA*, 300, 2765–2778.
- Bouvard, V., Loomis, D., Guyton, K. Z., Grosse, Y., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Mattock, H., Straif, K., & International Agency for Research on Cancer Monograph Working, G. (2015). Carcinogenicity of consumption of red and processed meat. *The Lancet Oncology*, 16, 1599–1600.
- Boyle, T., Keegel, T., Bull, F., Heyworth, J., & Fritschi, L. (2012). Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. *Journal of the National Cancer Institute*, 104, 1548–1561.
- Canavan, C., Abrams, K. R., & Mayberry, J. (2006). Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. *Alimentary Pharmacology & Therapeutics*, 23, 1097–1104.
- CDC. (2019). Changes over time: All types of cancer (Centers for Disease Control and Prevention. <https://gis.cdc.gov/Cancer/USCS/DataViz.html>).
- Chassard, C., Delmas, E., Robert, C., & Bernalier-Donadille, A. (2010). The cellulose-degrading microbial community of the human gut varies according to the presence or absence of methanogens. *FEMS Microbiology Ecology*, 74, 205–213.
- Cockburn, D. W., Orlovsky, N. I., Foley, M. H., Kwiatkowski, K. J., Bahr, C. M., Maynard, M., Demeler, B., & Koropatkin, N. M. (2015). Molecular details of a starch utilization pathway in the human gut symbiont *Eubacterium rectale*. *Molecular Microbiology*, 95, 209–230.
- Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L. (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. *International Journal of Molecular Sciences*, 14, 16365–16385.
- Cougnoux, A., Dalmasso, G., Martinez, R., Buc, E., Delmas, J., Gibold, L., Sauvanet, P., Darcha, C., Dechelotte, P., Bonnet, M., et al. (2014). Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. *Gut*, 63, 1932–1942. Cuevas-Ramos, G., Petit, C. R., Marcq, I., Boury, M., Oswald, E., & Nougayrede, J. P. (2010). *Escherichia coli* induces DNA damage in vivo and triggers genomic instability in

- mammalian cells. *Proceedings of the National Academy of Sciences of the United States of America*, 107, 11537–11542.
- Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015). Portrait of the PI3K/AKT pathway in colorectal cancer. *Biochimica et Biophysica Acta*, 1855, 104–121.
- Ekbom, A., Helmick, C., Zack, M., & Adami, H. O. (1990). Ulcerative colitis and colorectal cancer. A population-based study. *The New England Journal of Medicine*, 323, 1228–1233.
- Fedirko, V., Tramacere, I., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Negri, E., Straif, K., Romieu, I., La Vecchia, C., et al. (2011). Alcohol drinking and colorectal cancer risk: an over-all and dose-response meta-analysis of published studies. *Annals of Oncology*, 22, 1958–1972.
- Feng, Q., Liang, S., Jia, H., Stadlmayr, A., Tang, L., Lan, Z., Zhang, D., Xia, H., Xu, X., Jie, Z., et al. (2015). Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nature Communications*, 6, 6528.
- Flanagan, L., Schmid, J., Ebert, M., Soucek, P., Kunicka, T., Liska, V., Bruha, J., Neary, P., Dezeeuw, N., Tommasino, M., et al. (2014). Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *European Journal of Clinical Microbiology & Infectious Diseases*, 33, 1381–1390.
- Flemer, B., Lynch, D. B., Brown, J. M., Jeffery, I. B., Ryan, F. J., Claesson, M. J., O'Riordain, M., Shanahan, F., & O'Toole, P. W. (2017). Tumour-associated and non-tumour-associated micro-biota in colorectal cancer. *Gut*, 66, 633–643.
- Gao, R., Kong, C., Li, H., Huang, L., Qu, X., Qin, N., & Qin, H. (2017). Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. *European Journal of Clinical Microbiology & Infectious Diseases*, 36, 2457–2468.
- Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Stanietsky-Kaynan, N., Copenhagen-Glazer, S., et al. (2015). Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity*, 42, 344–355.
- Half, E., Bercovich, D., & Rozen, P. (2009). Familial adenomatous polyposis. *Orphanet Journal of Rare Diseases*, 4, 22.
- Helander, H. F., & Fandriks, L. (2014). Surface area of the digestive tract - revisited. *Scandinavian Journal of Gastroenterology*, 49, 681–689.
- Henderson, T. O., Oeffinger, K. C., Whitton, J., Leisenring, W., Neglia, J., Meadows, A., Crotty, C., Rubin, D. T., Diller, L., Inskip, P., et al. (2012). Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. *Annals of Internal Medicine*, 156, 757–766, W-260.
- Hibberd, A. A., Lyra, A., Ouwehand, A. C., Rolny, P., Lindegren, H., Cedgard, L., & Wettergren, Y. (2017). Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. *BMJ Open Gastroenterology*, 4, e000145.
- Hugon, P., Dufour, J. C., Colson, P., Fournier, P. E., Sallah, K., & Raoult, D. (2015). A comprehensive repertoire of prokaryotic species identified in human beings. *The Lancet Infectious Diseases*, 15, 1211–1219.
- Jess, T., Loftus, E. V., Jr., Velayos, F. S., Harmsen, W. S., Zinsmeister, A. R., Smyrk, T. C., Schleck, C. D., Tremaine, W. J., Melton, L. J., 3rd, Munkholm, P., et al. (2006). Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. *Gastroenterology*, 130, 1039–1046.
- Jones, S., Chen, W. D., Parmigiani, G., Diehl, F., Beerenswinkel, N., Antal, T., Traulsen, A., Nowak, M. A., Siegel, C., Velculescu, V. E., et al. (2008). Comparative lesion sequencing provides insights into tumor evolution. *Proceedings of the National Academy of Sciences of the United States of America*, 105, 4283–4288.
- Karahalios, A., English, D. R., & Simpson, J. A. (2015). Weight change and risk of colorectal cancer: a systematic review and meta-analysis. *American Journal of Epidemiology*, 181,

- 832–845. Khan, M. T., Duncan, S. H., Stams, A. J., van Dijl, J. M., Flint, H. J., & Harmsen, H. J. (2012). The gut anaerobe *Faecalibacterium prausnitzii* uses an extracellular electron shuttle to grow at oxic-anoxic interphases. *The ISME Journal*, 6, 1578–1585.
- Koliada, A., Syzenko, G., Moseiko, V., Budovska, L., Puchkov, K., Perederiy, V., Gavalko, Y., Doroфeyev, A., Romanenko, M., Tkach, S., et al. (2017). Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. *BMC Microbiology*, 17, 120.
- Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012). Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Research*, 22, 292–298.
- Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013). *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host & Microbe*, 14, 207–215.
- Kulaylat, M. N., & Dayton, M. T. (2010). Ulcerative colitis and cancer. *Journal of Surgical Oncology*, 101, 706–712.
- Leitch, E. C., Walker, A. W., Duncan, S. H., Holtrop, G., & Flint, H. J. (2007). Selective colonization of insoluble substrates by human faecal bacteria. *Environmental Microbiology*, 9, 667–679.
- Li, X. L., Zhou, J., Chen, Z. R., & Chng, W. J. (2015). P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. *World Journal of Gastroenterology*, 21, 84–93.
- Liu, L., Tabung, F. K., Zhang, X., Nowak, J. A., Qian, Z. R., Hamada, T., Nevo, D., Bullman, S., Mima, K., Kosumi, K., et al. (2018). Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain *Fusobacterium nucleatum*. *Clinical Gastroenterology and Hepatology*, 16(1622–1631), e1623.
- Lopez-Siles, M., Martinez-Medina, M., Suris-Valls, R., Aldeguer, X., Sabat-Mir, M., Duncan, S. H., Flint, H. J., & Garcia-Gil, L. J. (2016). Changes in the Abundance of *Faecalibacterium prausnitzii* Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer. *Inflammatory Bowel Diseases*, 22, 28–41.
- Lynch, H. T., & de la Chapelle, A. (2003). Hereditary colorectal cancer. *The New England Journal of Medicine*, 348, 919–932.
- Lynch, H. T., & Krush, A. J. (1971). Cancer family "G" revisited: 1895–1970. *Cancer*, 27, 1505–1511.
- Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014). A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut*, 63, 1275–1283.
- Mendez-Salazar, E. O., Ortiz-Lopez, M. G., Granados-Silvestre, M. L. A., Palacios-Gonzalez, B., & Menjivar, M. (2018). Altered Gut Microbiota and Compositional Changes in Firmicutes and Proteobacteria in Mexican Undernourished and Obese Children. *Frontiers in Microbiology*, 9, 2494.
- Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016). *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut*, 65, 1973–1980.
- Munkholm, P. (2003). Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 18(Suppl 2), 1–5.
- Rossi, O., van Berkel, L. A., Chain, F., Tanweer Khan, M., Taverne, N., Sokol, H., Duncan, S. H., Flint, H. J., Harmsen, H. J., Langella, P., et al. (2016). *Faecalibacterium prausnitzii* A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. *Scientific Reports*, 6, 18507.

- Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., & Han, Y. W. (2013). *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. *Cell Host & Microbe*, 14, 195–206.
- Salyers, A. A., West, S. E., Vercellotti, J. R., & Wilkins, T. D. (1977). Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. *Applied and Environmental Microbiology*, 34, 529–533.
- Sears, C. L. (2009). Enterotoxigenic *Bacteroides fragilis*: a rogue among symbionts. *Clinical Microbiology Reviews*, 22, 349–369, Table of Contents.
- Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: a Cancer Journal for Clinicians*, 69, 7–34.
- Sun, X., & Jia, Z. (2018). Microbiome modulates intestinal homeostasis against inflammatory diseases. *Veterinary Immunology and Immunopathology*, 205, 97–105.
- Taylor, D. P., Burt, R. W., Williams, M. S., Haug, P. J., & Cannon-Albright, L. A. (2010). Population-based family history-specific risks for colorectal cancer: a constellation approach. *Gastroenterology*, 138, 877–885.
- Thiele Orberg, E., Fan, H., Tam, A. J., Dejea, C. M., Destefano Shields, C. E., Wu, S., Chung, L., Finard, B. B., Wu, X., Fathi, P., et al. (2017). The myeloid immune signature of enterotoxigenic *Bacteroides fragilis*-induced murine colon tumorigenesis. *Mucosal Immunology*, 10, 421–433.
- Thomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F., Manara, S., Karcher, N., Pozzi, C., et al. (2019). Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. *Nature Medicine*, 25, 667–678.
- Toprak, N. U., Yagci, A., Gulluoglu, B. M., Akin, M. L., Demirkalem, P., Celenk, T., & Soyletir, G. (2006). A possible role of *Bacteroides fragilis* enterotoxin in the aetiology of colorectal cancer. *Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*, 12, 782–786.
- Tuohy, T. M., Rowe, K. G., Mineau, G. P., Pimentel, R., Burt, R. W., & Samadder, N. J. (2014). Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah. *Cancer*, 120, 35–42.
- Wedeckind, K. J., Mansfield, H. R., & Montgomery, L. (1988). Enumeration and isolation of cellulolytic and hemicellulolytic bacteria from human feces. *Applied and Environmental Microbiology*, 54, 1530–1535.
- Weir, T. L., Manter, D. K., Sheflin, A. M., Barnett, B. A., Heuberger, A. L., & Ryan, E. P. (2013). Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. *PLoS One*, 8, e70803.
- Winther, K. V., Jess, T., Langholz, E., Munkholm, P., & Binder, V. (2004). Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. *Clinical Gastroenterology and Hepatology*, 2, 1088–1095.
- Wirbel, J., Pyl, P. T., Kartal, E., Zych, K., Kashani, A., Milanese, A., Fleck, J. S., Voigt, A. Y., Paljeja, A., Ponnudurai, R., et al. (2019). Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nature Medicine*, 25, 679–689.
- Wu, S., Morin, P. J., Maouyo, D., & Sears, C. L. (2003). *Bacteroides fragilis* enterotoxin induces c-Myc expression and cellular proliferation. *Gastroenterology*, 124, 392–400.
- Yang, Y., Weng, W., Peng, J., Hong, L., Yang, L., Toiyama, Y., Gao, R., Liu, M., Yin, M., Pan, C., et al. (2017). *Fusobacterium nucleatum* Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kappaB, and Up-regulating Expression of MicroRNA-21. *Gastroenterology*, 152(851–866), e824.
- Yuhara, H., Steinmaus, C., Cohen, S. E., Corley, D. A., Tei, Y., & Buffler, P. A. (2011). Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *The American Journal*

- nal of Gastroenterology, 106, 1911–1921; quiz 1922.
- Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., et al. (2017). Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. *Journal of Clinical Oncology*, 35, 1086–1095.
- Ze, X., Duncan, S. H., Louis, P., & Flint, H. J. (2012). *Ruminococcus bromii* is a keystone species for the degradation of resistant starch in the human colon. *The ISME Journal*, 6, 1535–1543.
- Zeller, G., Tap, J., Voigt, A. Y., Sunagawa, S., Kultima, J. R., Costea, P. I., Amiot, A., Bohm, J., Brunetti, F., Habermann, N., et al. (2014). Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*, 10, 766.